Buying pressure lifts Moderna higher in today trading

Traders Union
All News
Financial News
Moderna rises 2.08% to $43.11 today

Highlights

The European Commission approved Moderna's mNEXSPIKE (mRNA-1283) COVID-19 vaccine for individuals aged 12 and older, expanding its international market access.
The FDA issued a refuse-to-file letter for Moderna's mRNA-1010 flu vaccine, prompting the company to halt late-stage US studies while focusing on global regulatory strategies.
MRNA trades at $43.11, just below resistance at $45 and dynamic Ichimoku support at $43.79, with momentum indicators suggesting a strongly bullish short-term technical outlook.

Regulatory setbacks drive divergent market sentiment and flows

The European Commission approved Moderna's COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for use in individuals 12 years and older. In the US, the FDA issued a refuse-to-file letter for the mRNA-1010 flu vaccine, leading Moderna to halt late-stage vaccine studies domestically. The company continues to advance updated vaccines and pursue international regulatory pathways.

Anton Kharitonov, expert at Traders Union, notes that Moderna’s recent strength is mainly technical, but short-term resistance and overbought signals raise caution. He highlights that the FDA’s refusal of the mRNA-1010 flu vaccine in the US poses a material setback, overshadowing the European approval’s positive impact. The technical uptrend looks robust for now, but volatility and divergent indicators warn of an unstable rally. Kharitonov stresses that the price is highly sensitive to further regulatory headlines, and adverse news could reverse gains quickly. "While momentum persists, I see significant downside risks for those chasing upside without tactical stop loss discipline."

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s trajectory as fundamentally resilient and sees the European regulatory approval as a key positive driver. He believes the bullish structure remains intact despite US headwinds and expects further growth as the company advances new vaccines and pursues international markets. Technical momentum and broad institutional support offer a constructive backdrop for medium-term gains. Karapetjanc asserts that new highs are likely as long as the price sustains above $43.79. "With market confidence and strong technicals lining up, I expect Moderna to unlock multiple bullish setups in the days ahead."

Overbought signals surface as bullish momentum clashes with resistance

This setup suggests some short-term resistance, though the broader technical structure remains strongly bullish, with dynamic Ichimoku support at $43.79 and next resistance likely forming at the $45 round level. Momentum indicators on the daily chart are mostly bullish, with MACD signaling a strong buy and ADX at 33.16, confirming the strength of the current uptrend. RSI is in neutral-to-bullish territory at 53.98, while Stoch RSI offers strong buy signals and CCI remains neutral; however, the BBP indicates an overbought condition, suggesting buyers dominate intraday momentum. The Awesome Oscillator sits neutral and does not strongly support today's move. There is some divergence as overbought signals and strong momentum coexist, indicating the current bullish tone may face short-term pullbacks.

Previously it was reported that Moderna expanded its vaccine portfolio following European approval for mNEXSPIKE® targeting individuals aged 12 and above. The asset's recent momentum appears positive on growing market confidence, with key moving averages trending upwards and technical indicators such as RSI and MACD signaling continued bullish sentiment above established support levels.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.